Myriad Genetics (MYGN) Receives $30.45 Average Price Target from Brokerages

Myriad Genetics (NASDAQ:MYGN) has been given an average rating of “Hold” by the fourteen brokerages that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have given a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $30.45.

Several research firms recently commented on MYGN. BTIG Research set a $44.00 price target on shares of Myriad Genetics and gave the stock a “buy” rating in a report on Wednesday, February 7th. Leerink Swann raised their price target on shares of Myriad Genetics from $33.00 to $35.00 and gave the stock a “market perform” rating in a report on Wednesday, February 7th. BidaskClub cut shares of Myriad Genetics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 28th. ValuEngine cut shares of Myriad Genetics from a “buy” rating to a “hold” rating in a report on Tuesday, March 13th. Finally, Morgan Stanley upgraded shares of Myriad Genetics from an “underweight” rating to an “equal weight” rating and set a $28.00 price target for the company in a report on Wednesday, March 21st.

How to Become a New Pot Stock Millionaire

In other news, VP Richard M. Marsh sold 37,654 shares of Myriad Genetics stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $40.25, for a total value of $1,515,573.50. Following the transaction, the vice president now owns 157,648 shares of the company’s stock, valued at $6,345,332. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Gary A. King sold 3,120 shares of Myriad Genetics stock in a transaction that occurred on Thursday, January 18th. The shares were sold at an average price of $38.12, for a total transaction of $118,934.40. Following the completion of the transaction, the vice president now directly owns 125,088 shares in the company, valued at approximately $4,768,354.56. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 54,533 shares of company stock worth $2,133,272. Insiders own 6.70% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. Xact Kapitalforvaltning AB bought a new position in shares of Myriad Genetics in the fourth quarter valued at approximately $261,000. MetLife Investment Advisors LLC bought a new position in shares of Myriad Genetics in the fourth quarter valued at approximately $1,022,000. BB&T Securities LLC raised its position in shares of Myriad Genetics by 347.7% in the fourth quarter. BB&T Securities LLC now owns 5,990 shares of the company’s stock valued at $205,000 after purchasing an additional 4,652 shares during the period. Macquarie Group Ltd. raised its position in shares of Myriad Genetics by 7.8% in the fourth quarter. Macquarie Group Ltd. now owns 145,500 shares of the company’s stock valued at $4,998,000 after purchasing an additional 10,500 shares during the period. Finally, Vident Investment Advisory LLC raised its position in shares of Myriad Genetics by 6.5% in the fourth quarter. Vident Investment Advisory LLC now owns 115,121 shares of the company’s stock valued at $3,954,000 after purchasing an additional 7,029 shares during the period.

Shares of MYGN stock traded down $0.51 during trading on Wednesday, hitting $29.04. 501,441 shares of the company were exchanged, compared to its average volume of 724,677. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.81 and a current ratio of 2.05. The stock has a market cap of $2,064.08, a P/E ratio of 27.68, a P/E/G ratio of 2.08 and a beta of 0.52. Myriad Genetics has a twelve month low of $17.50 and a twelve month high of $41.57.

Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.24 by $0.07. The business had revenue of $194.00 million during the quarter, compared to analysts’ expectations of $188.72 million. Myriad Genetics had a net margin of 16.67% and a return on equity of 9.59%. The firm’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same period last year, the company posted $0.26 earnings per share. sell-side analysts predict that Myriad Genetics will post 1.15 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Myriad Genetics (MYGN) Receives $30.45 Average Price Target from Brokerages” was originally posted by Enterprise Leader and is the sole property of of Enterprise Leader. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://theenterpriseleader.com/2018/04/02/myriad-genetics-mygn-receives-30-45-average-price-target-from-brokerages.html.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply